|1.||Santos-Lima, Eduardo: 8 articles (08/2013 - 04/2011)|
|2.||Ortiz, Esteban: 7 articles (05/2012 - 03/2009)|
|3.||Friedland, Leonard R: 5 articles (02/2015 - 11/2008)|
|4.||Miller, Jacqueline M: 4 articles (02/2015 - 01/2010)|
|5.||Blatter, Mark: 4 articles (02/2015 - 01/2010)|
|6.||Zambrano, Betzana: 4 articles (10/2012 - 06/2011)|
|7.||Chuenkitmongkol, Sunate: 4 articles (05/2012 - 03/2009)|
|8.||Pancharoen, Chitsanu: 4 articles (05/2012 - 03/2009)|
|9.||Thisyakorn, Usa: 4 articles (03/2012 - 03/2009)|
|10.||Groome, Michelle: 3 articles (08/2013 - 04/2011)|
08/01/1993 - "To study the safety, immunogenicity, and protective efficacy of the Haemophilus influenzae capsular polysaccharide tetanus conjugate vaccine (PRP-T). "
03/01/1997 - "The reduction in anti-PRP antibody in mothers receiving PRP-T conjugate vaccine within 4 weeks of a tetanus shot, however, demonstrates the necessity to demonstrate immunogenicity, safety, and efficacy of maternal immunization strategies before universal implementation. "
05/15/2014 - "However, additional molecular size parameters (i.e., molar mass and hydrodynamic radius) are necessary for a reliable characterization of the tetanus conjugate (PRP-T), certainly due to the lattice-like structure of the conjugate. "
08/01/1998 - "A polyribosylribitol phosphate (polysaccharide)-tetanus protein conjugate vaccine (PRP-T) against Haemophilus influenzae type b (Hib) was evaluated for protective immunogenicity in 25 previously PRP-unimmunized children who had failed to develop protective PRP antibody levels (< 1 microg/ml) after prior invasive Hib disease at median age 10 months. "
04/01/1998 - "In addition concomitant PRP-T (either simultaneous or combined) with DTaP-eIPV lowered anti-PRP and further decreased tetanus GMTs. "
|2.||Whooping Cough (Pertussis)
03/01/2009 - "Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine."
01/01/2001 - "Haemophilus influenzae type b vaccine: reconstitution of lyophilised PRP-T vaccine with a pertussis-containing paediatric combination vaccine, or a change in the primary series immunisation schedule, may modify the serum anti-PRP antibody responses."
04/01/1998 - "In contrast concomitant PRP-T with DTaP-eIPV enhanced the pertussis GMTs. "
12/01/1996 - "The incidence of pertussis was similar among infants assigned to health centers administering combined PRP-T/DTP and those administering DTP alone (13.1 vs. 12.2 cases/10(5) child-years). "
12/01/1996 - "Combined PRP-T/DTP vaccine did not diminish protection against pertussis."
05/16/1998 - "627 Chilean infants were randomly allocated to one of four regimens with either Hib polysaccharide-tetanus toxoid conjugate vaccine (PRP-T) or Hib oligosaccharide-diphtheria mutant toxoid conjugate vaccine (PRP-CRM197), for a total of eight groups. "
04/01/1998 - "After boosting with DTaP/PRP-T decreased GMTs to diphtheria and PRP antigens were observed in the groups that received DTaP and eIPV combined. "
08/01/1991 - "Hib-TT elicited fewer local reactions than diphtheria-tetanus toxoid vaccine. "
06/01/2002 - "In order to identify more economical vaccination schedules, we carried out a trial to evaluate the immunogenicity of an alternative two-dose PRP-T regimen, based on a previous report in which carrier priming could be obtained with prior diphtheria-tetanus-pertussis (DTP) vaccination. "
01/01/2005 - "Children were immunised (WHO schedule) with diphtheria, tetanus, pertussis (DTP) or DTP-PRP-T (Hib conjugate) vaccine. "
02/18/2013 - "All seroprotection (D, T, polio-1, -2, -3, Hep B, PRP-T [Hib]), seroconversion (PT and FHA), and vaccine response (PT and FHA) data were high, and were similar to licensed comparators (pooled SP, SC, and VR rates were 97.1-100%, 96.0-97.0%, and 99.7-99.9%, respectively). "
02/24/2011 - "Infants (N=792) were randomly assigned to receive DTaP-IPV//PRP-T at 2, 3 and 4 months of age (Group A) or 3, 4 and 5 months of age (Group B), or DTaP (Wuhan Institute of Biological Products), PRP-T (Act-Hib(®)) and IPV (Imovax(®) Polio) at 3, 4 and 5 months of age (Group C). "
01/01/1999 - "DTaP, PRP-T, and oral poliomyelitis vaccine (OPV) were given at 2, 4, 6, and 18 months. "
04/01/1998 - "Infants (n=711) were randomly assigned to receive 1 of 5 regimens as the primary series at 2, 4 and 6 months of age, by group: (1) DTaP plus oral polio vaccine (OPV); (2) DTaP plus eIPV (separate injections); (3) DTaP-eIPV combined as a single injection; (4) DTaP-eIPV combined, plus a separate injection of PRP-T; or (5) DTaP-eIPV combined and reconstituting PRP-T, as a single injection. "
04/01/1995 - "Combining PRP-T and DTP produced a combination vaccine associated with a slight increase in the rate of erythema and swelling but with similar immunogenicity of the vaccine components and oral polio vaccine."
10/01/2008 - "We hope that Hib meningitis will be eliminated by the routine shots of ActHIB under immunization low in near future."
04/01/1996 - "A 4 month-old infant was admitted for a severe form of Hib meningitis with septicemia whose first manifestations developed 3 hours after the first immunization with a conjugate vaccine against Hib (PRP-T). "
02/01/1991 - "We conclude that Hib-TT, injected at 3, 5, 7, and 18 months, is safe and induces protective levels of antibodies during the age of highest incidence of meningitis caused by Hib."
01/01/1994 - " Advantages of the PRP-T vaccine include: it mixes well with DPT; if administered in a three-dose schedule to Gambian infants, it is safe and elicits a protective antibody response in most infants; and it also protects against Hib infection, a major cause of meningitis and pneumonia in infants and an important cause of major childhood-acquired disability in developing countries."
04/26/1997 - "PRP-T conjugate Hib vaccine prevented most cases of meningitis and pneumonia due to Hib in Gambian infants. "
|1.||Diphtheria-Tetanus-Pertussis Vaccine (DPT Vaccine)
|4.||Tetanus Toxoid (Vaccine, Tetanus)
|7.||Diphtheria-Tetanus-acellular Pertussis Vaccines (Tripedia)
|9.||Inactivated Poliovirus Vaccine (Salk Vaccine)